Dr. Jason Lewis and Dr. Thomas Ruth, worldwide acknowledged leaders in the radiopharmaceutical space, to sign up with Alpha-9’s SAB
BOSTON and VANCOUVER, BC, March 7, 2023 /PRNewswire/ — Alpha-9 Theranostics, a scientific phase biotechnology business establishing distinguished and extremely targeted radiopharmaceuticals, today revealed the appointment of Jutta Wanner, Ph.D. as Senior Vice President of Drug Discovery. The business likewise revealed the visits of Jason Lewis, Ph.D. and Tom Ruth, Ph.D. to the recently formed Scientific Advisory Board.
“We are enjoyed invite these professionals to our group,” said David Hirsch, M.D., Ph.D., CEO of Alpha-9. “The addition of their understanding and experience will accelerate our business’s development.”
Dr. Jutta Wanner, who brings over twenty years of drug discovery experience, will lead discovery and early phase advancement of the business’s programs and supervise the growth of Alpha-9’s pipeline. Her experience consists of leading little particle and targeted drug conjugate tasks as the CSO and CTO of several biotechnology companies, along with a years at Hoffmann-La Roche in a variety of drug discovery functions.
“I have actually followed the advancements in radiopharmaceuticals over the previous years as the field has actually made considerable developments in producing extremely effective and bearable representatives. I genuinely think that radiopharmaceuticals will supply unique treatment choices for clients,” said Dr. Wanner. “Alpha-9 has a well-rounded and educated group, interesting information, and the resources to effectively bring the next set of substances into the center and beyond. I am delighted to build out the R&D group and eagerly anticipate moving into our brand-new laboratory space.”
Dr. Jason Lewis brings deep competence in the advancement and translation of radiopharmaceuticals from years of research study establishing little- and biomolecule-based therapies and diagnostics. He is the Emily Tow Jackson Chair at Memorial Sloan Kettering Cancer Center in New York along with the Vice Chair for Research for the Department of Radiology, Chief Attending of the Radiochemistry and Imaging Sciences Service, and Co-Director of the Radiochemistry and Molecular Imaging Probe Core Facility.
Dr. Thomas Ruth brings more than 5 years of experience in the production and application of radioisotopes for research study in the physical and life sciences. He is an Emeritus Senior Research Scientist at TRIUMF and Emeritus Senior Scientist at the British Columbia Cancer Research Centre. A leader in the production and application of radioisotopes for research study in the physical and life sciences, he has actually served on a plethora of nationwide and worldwide committees (USDOE, NAS, IAEA). Dr. Ruth was the Director for the UBC/TRIUMF FAMILY PET Program for over twenty years, throughout which time he supervised the setup of several cyclotrons and animal scanners at UBC. Dr. Ruth is likewise a Fellow of the Royal Society of Canada.
About Alpha-9
Alpha-9 Theranostics is a scientific phase, radiopharmaceutical business establishing distinguished and extremely targeted radiopharmaceuticals with the possible to meaningfully enhance the treatment of individuals dealing with cancer. Applying exclusive innovations and deep-foundational competence, Alpha-9 is on the leading edge of engineering bespoke radiopharmaceuticals that are enhanced to selectively provide radiation to growth websites while reducing off-target impacts. Alpha-9 is advancing a robust pipeline of unique radiopharmaceuticals with a methodical technique to particle style that provides broad capacity for growth into a number of confirmed oncology targets. For more info, please check out www.alpha9tx.com.
View initial material to download multimedia: https://www.prnewswire.com/news-releases/alpha-9-theranostics-strengthens-its-scientific-expertise-with-key-appointments-to-leadership-team-and-scientific-advisory-board-301763473.html
SOURCE Alpha-9 Theranostics Inc.
